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for m alignant conversion In EV cases induced primarily by 
HPV-3. 
Since t here are clear differences in oncogenic potential be-
tween HPV -3 and HPV -4, identification of the type of infecting 
virus by the IF method is very important both for the diagnosis 
of EV a nd prognosis. 
The IF method was found useful for the detection of wart 
viruses if purified wart virus preparations were used [20,21]' 
Yabe a nd Sadaka ne [21] used purified virus antiserum prepared 
from pooled verrucae vulgares, and this may perhaps be t he 
explanation as to why their sera were more effective in dem-
onstrating HPV in warts a nd wart-like EV lesions t han are 
t hose prepared from viruses of pooled warts with predomina ntly 
t h e virus of pla ntar wart, which are commonly used for immu-
nologic studies of warts. 
In our work t he ant isera were prepared from viruses isolated 
fro m single patients infected with HPV -3 and HPV -4, and this 
made possible their differentiation [1 8]. 
When t he HPV-4 type is demonstrated in wart-like and / or 
plaque lesions, diagnosis of EV is practically confirmed and 
malignant transformation is very probable. 
Studies of the specific humoral immunity and nonspecific 
e MI a re of no significance for differentiation between EV and 
lo n g-standing warts. The specific humoral immunity seems to 
be somewhat depressed both in patients with HPV-3 induced 
EV a nd long-lasting warts, but our material is still not sufficient 
to evaluate its rol e. 
U sually not all the CMI tests show abnormalities, so that 
c u taneous sensitizat ion to DNCB seems to be the most reliable 
index. 
Study of nonspecific CMI may be of some importance for 
evaluating the cou rse of the disease and for the prognosis in 
cases of either EV or flat warts. CM! was normal in 2 nonpro-
gressing cases of EV a nd in the son of a patient with EV who 
remained healthy after the removal of wa rt-like lesions. It also 
was norma l in cases of flat warts with ·a tendency to involution. 
Our findings seem to provide an explanation why cases of EV 
differ in their clinical and histologic appearance, course, and 
expectancy of malignant conversion. The identification of the 
HPV type offers some possibility of predicting the course of the 
disease and potential malignancy. On the other hand , there are 
no reliable clinical, histologic, and immunologic criteria for 
differentiating between long-standing fl at warts and HPV-3-
induced EV cases. 
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Announcement 
At its fourth World Congress to be held at New Orleans October 1979, the International Society of 
Tropical Dermatology bestows its customary memorial medal and award for ~)Utstanding research 
presented in a paper on D ermatology or Dermatology-related ecology. InternatIOnal person~, please 
contact: chairman, Castellani-Reiss M emorial Medal Committee, Prof. Kasuke Ito M.D., HonJo-Izumo 
1-3604, Gifu City, Japan. 
Papers to be submitted by April 30, 1979. 
